<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04245085</url>
  </required_header>
  <id_info>
    <org_study_id>ETOP 15-19</org_study_id>
    <secondary_id>MO40586</secondary_id>
    <nct_id>NCT04245085</nct_id>
  </id_info>
  <brief_title>ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma</brief_title>
  <acronym>ABC-lung</acronym>
  <official_title>A Randomised Non-comparative Open Label Phase II Trial of Atezolizumab Plus Bevacizumab, With Carboplatin-paclitaxel or Pemetrexed, in EGFR-mutant Non-small Cell Lung Carcinoma With Acquired Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Thoracic Oncology Platform</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Thoracic Oncology Platform</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ETOP 15-19 ABC-lung is an international, multi-centre open-label, randomized phase II trial
      with two non-comparative parallel arms of atezolizumab plus bevacizumab with
      carboplatin-paclitaxel (Arm A) or atezolizumab, bevacizumab and pemetrexed (Arm B) in
      patients with stage IIIB-IV non-squamous non-small cell lung cancer (NSCLC) harbouring EGFR
      mutations after failure of standard EGFR tyrosine kinase inhibitors (TKIs).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 30, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) rate at 12 months according to RECIST v1.1</measure>
    <time_frame>12 months from randomisation</time_frame>
    <description>The primary objective of this study is to explore the clinical efficacy of atezolizumab and bevacizumab combined with chemotherapy in patients with EGFR-mutant advanced NSCLC after failure of standard EGFR TKIs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events according to CTCAE v5.0</measure>
    <time_frame>from the date of randomisation until 90 days after the last dose of protocol treatment</time_frame>
    <description>To assess the safety and tolerability of the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>through study completion, from the date of randomisation until death, including OS rate at 12 months.</time_frame>
    <description>OS is defined as the time from the date of randomisation until death from any cause. Censoring will occur at the last follow-up date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
    <time_frame>From date of randomisation until date of treatment completion (until documented disease progression, death or any other causes), assessed up to 2 years.</time_frame>
    <description>Objective response is defined as best overall response (CR or PR) across all assessment time-points according to RECIST criteria v1.1, from randomisation until the end of protocol treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Core Questionnaire (EORTC QLQ-C30)</measure>
    <time_frame>from baseline up to 12 months or until disease progression, whatever is first.</time_frame>
    <description>Quality of life will be assessed by the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30). The key QoL outcome is the time to deterioration (TTD) in the QLQ-C30 global health status/global QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life lung cancer-specific module (QLQ-LC13)</measure>
    <time_frame>from baseline up to 12 months or until disease progression, whatever is first.</time_frame>
    <description>Lung cancer associated symptoms will be measured by the lung cancer-specific module (QLQ-LC13).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extra-cranial PFS</measure>
    <time_frame>through study completion, from date of randomisation to documentation of PD outside the CNS, assessed up to 2 years</time_frame>
    <description>Extra-cranial progression-free-survival is the time from randomisation to documentation of disease progression outside the central nervous system (CNS) as per RECIST criteria or death, whichever occurred first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial PFS</measure>
    <time_frame>through study completion, from date of randomisation to first documented radiographic evidence of CNS progression, assessed up to 2 years.</time_frame>
    <description>Intracranial progression-free-survival is defined as the time from randomisation to first documented radiographic evidence of CNS progression. CNS progression is defined as progression due to newly developed CNS lesions and/or progression of pre-existing baseline CNS lesions.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">95</enrollment>
  <condition>EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atezolizumab (1200 mg) Q3W, until PD
Bevacizumab (15 mg/kg), Q3W, until PD
Carboplatin (AUC5) Q3W, 4-6 cycles
Paclitaxel (200 mg/m2), Q3W, 4-6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atezolizumab (1200 mg), Q3W, until PD
Bevacizumab (15 mg/kg), Q3W, until PD
Pemetrexed (500 mg/m2), Q3W, until PD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Patients in both treatment arms will receive atezolizumab at a fixed dose of 1200 mg i.v. on day one of every 3-week (3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.
Treatment beyond RECIST-defined progression will be allowed if patient is continuing to derive clinical benefit.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Patients in both treatment arms will receive bevacizumab at a dose of 15 mg/kg i.v. on day one of every 3-week (+/- 3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Patients in treatment Arm A will receive carboplatin, AUC5 every 3 weeks for 4-6 cycles.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Patients in treatment Arm A will receive paclitaxel, 200 mg/m2, every 3 weeks for 4-6 cycles.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Patients in treatment Arm B will receive Pemetrexed, 500 mg/m2 every 3 weeks until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients (male/female) must be ≥18 years of age.

          2. Chemotherapy naïve, non-squamous NSCLC, stage IIIB/C (not amenable to radical therapy)
             or IV. Patients who have received previous adjuvant or neoadjuvant chemotherapy are
             eligible if the date of last dose of treatment was at least 12 months before
             randomisation.

          3. Known EGFR mutations genotypes by tissue or ctDNA, patients with common mutations
             (L858R or Del19) and other rare mutations (e.g. S768I, G719X) are eligible.

          4. Measurable or evaluable disease by RECIST v1.1.

          5. Disease progression (during or after) or unacceptable side effects from prior
             treatment with at least one EGFR TKI (washout period = 7 days).

             If most recent line of treatment (1st or 2nd line) was a third-generation EGFR TKI
             (e.g. osimertinib):

               -  Patient must be known to be EGFR mutation positive, either on fresh tumour biopsy
                  taken &gt;7 days prior to protocol treatment start or by recent ctDNA analysis
                  (informative ctDNA test, local test).

               -  T790M genotype is allowed

             If most recent line of treatment (1st or 2nd line) was a first- or second-generation
             EGFR TKI (e.g. afatinib, dacomitinib, erlotinib, gefitinib):

             - Patient must be known to be tissue EGFR T790M wild type (local test) on most recent
             line of EGFR TKI or if no tissue re-biopsy, no evidence of T790M on ctDNA but
             identified L858R, del19, S768I or G719X genotypes (informative ctDNA test, local test)

          6. Treatment with an EGFR TKI therapy for at least 10 days

          7. Adequate haematological function:

               -  Haemoglobin greater or equal 90 g/L

               -  Absolute neutrophils count (ANC) greater or equal 1.5× 109/L

               -  Platelet count greater or equal 100× 109/L

          8. Adequate renal function:

               -  Creatinine less or equal 1.5× ULN OR

               -  Creatinine clearance greater or equal 45 mL/min (using the Cockcroft-Gault
                  formula)

          9. Adequate liver function:

               -  ALT and AST less or equal 2.5× ULN. If the patient has liver metastases, ALT and
                  AST must be less or equal 5× ULN

               -  Total bilirubin less or equal 1.5x ULN.

         10. Willingness to provide any surplus tumour sample obtained at the time of acquired
             resistance to prior EGFR TKI

         11. Men and women of childbearing potential must agree to use adequate contraception

         12. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

         13. Life expectancy greater or equal 12 weeks

         14. Women of childbearing potential, including women who had their last menstrual period
             in the last 2 years, must have a negative serum or urine pregnancy test within 7 days
             before randomisation.

         15. Patient is willing and able to comply with the protocol for the duration of the trial
             including undergoing treatment and scheduled visits and examinations including follow
             up.

        Exclusion Criteria:

          1. Prior systemic cytotoxic chemotherapy for advanced stage NSCLC Patients who had
             received previous adjuvant or neoadjuvant chemotherapy are eligible if the last dose
             of treatment was at least 12 months before randomisation.

          2. Prior therapy with bevacizumab or other anti-angiogenic agent

          3. Prior immune checkpoint inhibitor therapy

          4. More than two lines of EGFR TKI therapy

          5. Known small-cell lung carcinoma (SCLC) or high grade neuroendocrine carcinoma (if
             progression biopsy has been performed locally).

          6. Squamous cell histologic subtype

          7. Known EGFR T790M positive genotype by tissue on most recent EGFR TKI progression or
             ctDNA and have not received an approved EGFR TKI targeting T790M (e.g. a
             third-generation EGFR TKI such as osimertinib).

          8. Active or untreated CNS metastases as determined by brain MRI

             - Patients with CNS metastases must be non-progressive by RECIST and symptomatically
             stable with no ongoing requirement for corticosteroids as therapy for CNS disease;
             anticonvulsants at a stable dose allowed

          9. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of
             radiation within 4 weeks of randomization.

         10. Presence or history of a malignant disease that has been diagnosed and/or required
             therapy within the past 3 years. Exceptions to this exclusion include the following:
             completely resected basal cell and squamous cell skin cancers, and completely resected
             carcinoma in situ of any type.

         11. Clear tumour infiltration into the thoracic great vessels (seen on imaging)

         12. QTc of grade ≥3 according to CTCAE v5.0

         13. Active autoimmune disease that has required systemic treatment in past 2 years.
             Patients with vitiligo, controlled type I diabetes mellitus on stable insulin, or
             residual autoimmune-related hypothyroidism only requiring hormone replacement or
             psoriasis not requiring systemic treatment are permitted

         14. Active or uncontrolled HIV, tuberculosis, hepatitis B or C infection

         15. Live attenuated vaccination within 4 weeks prior to randomisation.

         16. Subject receiving any biologic drugs targeting the immune system (for example, TNF
             blockers, anakinra, rituximab, abatacept, or tocilizumab).

         17. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest computed tomography scan. History of radiation pneumonitis in the radiation
             field (fibrosis) is permitted

         18. Inadequately controlled hypertension (defined as systolic blood pressure &gt;150 mmHg
             and/or diastolic blood pressure &gt;100 mmHg)

             - Anti-hypertensive therapy to achieve these parameters is allowable.

         19. Prior history of hypertensive crisis or hypertensive encephalopathy

         20. Significant vascular disease (e.g. aortic aneurysm requiring surgical repair or recent
             peripheral arterial thrombosis) within 6 months prior to randomization

         21. History of haemoptysis (greater or equal 2.5mL of bright red blood per episode) within
             1 month prior to randomization

         22. Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic
             anticoagulation)

         23. Current or recent (within 10 days of randomization) use of aspirin (&gt;325 mg/day) or
             treatment with dipyramidole, ticlopidine, clopidogrel, and clostazol

         24. Current use of full-dose oral or parenteral anticoagulants or thrombolytic agents for
             therapeutic purposes that has not been stable for &gt;2 weeks prior to randomization

               -  The use of full-dose oral or parenteral anticoagulants is permitted as long as
                  the INR or aPTT is within therapeutic limits (according to the medical standard
                  of the enrolling institution) and the patient has been on a stable dose of
                  anticoagulants for at least 2 weeks prior to randomization.

               -  Prophylactic anticoagulation for the patency of venous access devices is allowed,
                  provided the activity of the agent results in an INR &lt;1.5× ULN and aPTT is within
                  normal limits within 14 days prior to randomization.

               -  Prophylactic use of low-molecular-weight heparin (i.e., enoxaparin 40 mg/day) is
                  permitted.

         25. Core biopsy or other minor surgical procedure, excluding placement of a vascular
             access device, within 7 days prior to the first dose of bevacizumab

         26. History of abdominal or tracheoesophageal fistula or gastrointestinal perforation
             within 6 months prior to randomization

         27. Clinical signs of gastrointestinal obstruction or requirement for routine parenteral
             hydration, parenteral nutrition, or tube feeding

         28. Evidence of abdominal free air not explained by paracentesis or recent surgical
             procedure

         29. Serious, non-healing wound, active ulcer, or untreated bone fracture

         30. Proteinuria, as demonstrated by urine dipstick or &gt;1.0 g of protein in a 24-hour urine
             collection

             - All patients with greater or equal 2+ protein on dipstick urine alysis at baseline
             must undergo a 24 hour urine collection and must demonstrate lesser or equal 1 g of
             protein in 24 hours.

         31. Any unresolved toxicities from prior therapy greater than CTCAE v5.0 grade 1 at the
             time of starting trial treatment with the exception of alopecia

         32. History of hypersensitivity to the known active substances (atezolizumab, bevacizumab
             and chemotherapy drugs) or to any of the excipients.

         33. History of hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other
             recombinant human or humanised antibodies.

         34. Judgment by the Investigator that the patient should not participate in the study if
             the patient is unlikely to comply with study procedures, restrictions and
             requirements.

         35. Women who are pregnant or in the period of lactation.

         36. Sexually active men and women of childbearing potential who are not willing to use an
             effective contraceptive method during the trial and up to 6 months after discontinuing
             trial treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Susanne Roux</last_name>
    <phone>+41 31 511 94 17</phone>
    <email>ABC-lung@etop-eu.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heidi Roschitzki</last_name>
    <phone>+41 31 511 94 18</phone>
    <email>Heidi.Roschitzki@etop-eu.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LungenClinic Grosshansdorf</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Reck, MD</last_name>
    </contact>
    <investigator>
      <last_name>Martin Reck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Farastuk Bozorgmehr, MD</last_name>
    </contact>
    <investigator>
      <last_name>Farastuk Bozorgmehr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachkliniken München-Gauting</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Niels Reinmuth, MD</last_name>
    </contact>
    <investigator>
      <last_name>Niels Reinmuth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ji-Youn Han, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ji-Youn Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Byoung Chul Cho, MD</last_name>
    </contact>
    <investigator>
      <last_name>Byoung Chul Cho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ross Soo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ross Soo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO - Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Teresa Moran, MD</last_name>
    </contact>
    <investigator>
      <last_name>Teresa Moran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital De La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margarita Majem, MD</last_name>
    </contact>
    <investigator>
      <last_name>Margarita Majem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enriqueta Felip, MD</last_name>
    </contact>
    <investigator>
      <last_name>Enriqueta Felip, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OSI Bilbao Basurto</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria A Sala González, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria A Sala González, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana L Ortega Granados, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ana L Ortega Granados, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Teresa Herrera</name>
      <address>
        <city>La Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosario Garcia Campelo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rosario Garcia Campelo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Insular Gran Canaria</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Delvys Rodriguez Abreu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Delvys Rodriguez Abreu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mariano Provencio, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mariano Provencio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Díaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuel Domine, MD</last_name>
    </contact>
    <investigator>
      <last_name>Manuel Domine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Blasco, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ana Blasco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfredo Addeo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alfredo Addeo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Früh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Martin Früh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandra Curioni, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandra Curioni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Cancer Centre</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carles Escriu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carles Escriu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital (Fulham Road)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sanjay Popat, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sanjay Popat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital (Sutton)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sanjay Popat, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sanjay Popat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kent Oncology Centre</name>
      <address>
        <city>Maidstone</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Riyaz Shah, MD</last_name>
    </contact>
    <investigator>
      <last_name>Riyaz Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
  </removed_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

